Literature DB >> 31575497

Antihypertensive treatment with calcium channel blockers in patients with moderate or severe aortic stenosis: Relationship with all-cause mortality.

Sahrai Saeed1, Giuseppe Mancia2, Ronak Rajani3, Denise Parkin3, John B Chambers4.   

Abstract

BACKGROUND: Hypertension is common in patients with aortic stenosis (AS) and optimal blood pressure (BP) control is advised to reduce arterial load and cardiovascular events. Whether calcium channel blockers (CCB) are safe is not known.
METHODS: This was a retrospective analysis of 314 patients (age 65 ± 12 years, 68% men) with moderate or severe asymptomatic AS. Hypertension was defined from a history of hypertension, past or current antihypertensive treatment or a BP at the baseline clinic visit >140/90 mmHg. All patients underwent an exercise treadmill test (ETT) and echocardiography.
RESULTS: The prevalence of hypertension was 73.6%, and 65% took antihypertensive treatment. Patients who used a CCB (25%) (CCB+) were older, more likely to have hypercholesterolemia and coronary artery disease, and had higher systolic BP, stroke work, left ventricular mass compared to CCB-patients (all p < 0.05). During the baseline ETT, CCB+ patients achieved a lower peak heart rate, a shorter exercise time and were more likely to have a blunted BP response compared to CCB- patients (p < 0.05). Event-free survival was significantly lower in CCB+ than CCB- patients (all-cause mortality 16 [20.3%] versus 13 [5.6%]; p < 0.001). In a multivariable Cox regression model, CCB+ was associated with a 7-fold increased hazard ratio (HR) for all-cause mortality (HR 7.09; 95% CI 2.15-23.38, p = 0.001), independent of age, hypertension, diabetes, left ventricular ejection fraction, and aortic valve area.
CONCLUSION: The use of CCB was associated with an adverse effect on treadmill exercise and reduced survival in asymptomatic patients with moderate or severe AS.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antihypertensive treatment; Aortic stenosis, prognosis; Calcium channel blockers; Exercise treadmill test; Safety

Year:  2019        PMID: 31575497     DOI: 10.1016/j.ijcard.2019.09.007

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Medical management of symptomatic severe aortic stenosis in patients non-eligible for transcatheter aortic valve implantation.

Authors:  Gabriela Silvia Gheorghe; Andreea Simona Hodorogea; Andrei Cristian Dan Gheorghe; Ioan Tiberiu Nanea; Ana Ciobanu
Journal:  J Geriatr Cardiol       Date:  2020-11-28       Impact factor: 3.327

Review 2.  Arterial Hypertension in Aortic Valve Stenosis: A Critical Update.

Authors:  Christian Basile; Ilaria Fucile; Maria Lembo; Maria Virginia Manzi; Federica Ilardi; Anna Franzone; Costantino Mancusi
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

Review 3.  Exercise Testing in Aortic Stenosis: Safety, Tolerability, Clinical Benefits and Prognostic Value.

Authors:  Sahrai Saeed; John B Chambers
Journal:  J Clin Med       Date:  2022-08-25       Impact factor: 4.964

4.  Antihypertensive therapies in moderate or severe aortic stenosis: a systematic review and meta-analysis.

Authors:  Jonathan Sen; Erin Chung; Christopher Neil; Thomas Marwick
Journal:  BMJ Open       Date:  2020-10-05       Impact factor: 2.692

5.  Increased Ca2+ influx through CaV1.2 drives aortic valve calcification.

Authors:  Maiko Matsui; Rihab Bouchareb; Mara Storto; Yasin Hussain; Andrew Gregg; Steven O Marx; Geoffrey S Pitt
Journal:  JCI Insight       Date:  2022-03-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.